Francis I Baffour1, LaTonya J Hickson2, Mark D Stegall3, Patrick G Dean3, Tina M Gunderson4, Thomas D Atwell5, A Nicholas Kurup5, John J Schmitz6, Walter D Park7, Grant D Schmit6. 1. Department of Radiology, 200 First Street SW, Rochester, MN 55905. Electronic address: baffour.francis@mayo.edu. 2. Division of Nephrology and Hypertension, 200 First Street SW, Rochester, MN 55905. 3. Department of Medicine, Division of Transplant Surgery, 200 First Street SW, Rochester, MN 55905. 4. Department of Surgery, Division of Biomedical Statistics and Informatics, 200 First Street SW, Rochester, MN 55905. 5. Division of Ultrasound, 200 First Street SW, Rochester, MN 55905. 6. Division of Abdominal Imaging, 200 First Street SW, Rochester, MN 55905. 7. Division of Surgery Research Services, 200 First Street SW, Rochester, MN 55905; Department of Health Sciences Research, and William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Abstract
PURPOSE: To determine if patient aspirin exposure and timing affect bleeding risk after renal allograft biopsy. MATERIALS AND METHODS: Review of 6,700 renal allograft biopsies (in 2,362 unique patients) was performed. Median patient age was 53.0 years [interquartile range 43.0, 62.0]; 56.2% of patients were male. Of biopsies, 4,706 (70.2%) were performed in patients with no aspirin exposure within 10 days of biopsy; 664 (9.9%), were performed within 8-10 days of aspirin exposure; 855 (12.8%), within 4-7 days; and 475 (7.1%), within 0-3 days. Follow-up to 3 months after the procedure was completed in all patients. Biopsies were categorized as protocol or indication; 19.7% were indication biopsies. Bleeding complications were graded based on SIR criteria. Logistic regression models examined the association between aspirin use and bleeding events. RESULTS: Rate [95% confidence interval] of major bleeding complications was 0.24% [0.14, 0.39], and rate of any bleeding complication was 0.66% [0.46, 0.90]. Bleeding events were significantly associated with patients undergoing indication biopsies compared with protocol biopsies (odds ratio [OR] 2.27, P = .012). Patient factors associated with major bleeding complications in multivariate models included estimated glomerular filtration rate (OR 0.61, P = .016) and platelet count (OR 0.64, P = .033). Aspirin use was not significantly associated with increased risk of bleeding complication except for use of 325 mg of aspirin within 3 days of biopsy (any complication OR 3.87 [1.12, 13.4], P = .032; major complication OR 6.30 [1.27, 31.3], P = .024). CONCLUSIONS: Renal allograft biopsy bleeding complications are very rare, particularly for protocol biopsies. Use of 325 mg of aspirin within 3 days of renal allograft biopsy was associated with increased bleeding complications.
PURPOSE: To determine if patientaspirin exposure and timing affect bleeding risk after renal allograft biopsy. MATERIALS AND METHODS: Review of 6,700 renal allograft biopsies (in 2,362 unique patients) was performed. Median patient age was 53.0 years [interquartile range 43.0, 62.0]; 56.2% of patients were male. Of biopsies, 4,706 (70.2%) were performed in patients with no aspirin exposure within 10 days of biopsy; 664 (9.9%), were performed within 8-10 days of aspirin exposure; 855 (12.8%), within 4-7 days; and 475 (7.1%), within 0-3 days. Follow-up to 3 months after the procedure was completed in all patients. Biopsies were categorized as protocol or indication; 19.7% were indication biopsies. Bleeding complications were graded based on SIR criteria. Logistic regression models examined the association between aspirin use and bleeding events. RESULTS: Rate [95% confidence interval] of major bleeding complications was 0.24% [0.14, 0.39], and rate of any bleeding complication was 0.66% [0.46, 0.90]. Bleeding events were significantly associated with patients undergoing indication biopsies compared with protocol biopsies (odds ratio [OR] 2.27, P = .012). Patient factors associated with major bleeding complications in multivariate models included estimated glomerular filtration rate (OR 0.61, P = .016) and platelet count (OR 0.64, P = .033). Aspirin use was not significantly associated with increased risk of bleeding complication except for use of 325 mg of aspirin within 3 days of biopsy (any complication OR 3.87 [1.12, 13.4], P = .032; major complication OR 6.30 [1.27, 31.3], P = .024). CONCLUSIONS: Renal allograft biopsy bleeding complications are very rare, particularly for protocol biopsies. Use of 325 mg of aspirin within 3 days of renal allograft biopsy was associated with increased bleeding complications.
Authors: Peter N Furness; Carl M Philpott; Mary T Chorbadjian; Michael L Nicholson; Jean-Louis Bosmans; Bob L Corthouts; Johannes J P M Bogers; Anke Schwarz; Wilfried Gwinner; Hermann Haller; Michael Mengel; Daniel Seron; Francesc Moreso; Conception Cañas Journal: Transplantation Date: 2003-09-27 Impact factor: 4.939
Authors: Indravadan J Patel; Jon C Davidson; Boris Nikolic; Gloria M Salazar; Marc S Schwartzberg; T Gregory Walker; Wael A Saad Journal: J Vasc Interv Radiol Date: 2012-04-17 Impact factor: 3.464
Authors: D J Rea; J K Heimbach; J P Grande; S C Textor; S J Taler; M Prieto; T S Larson; F G Cosio; M D Stegall Journal: Kidney Int Date: 2006-09-06 Impact factor: 10.612
Authors: Wolfgang Grotz; Sylvia Siebig; Manfred Olschewski; Christoph W Strey; Karlheinz Peter Journal: Transplantation Date: 2004-06-27 Impact factor: 4.939
Authors: Kenaz Bakdash; Kristofer M Schramm; Aparna Annam; Matthew Brown; Kimi Kondo; Jonathan D Lindquist Journal: Semin Intervent Radiol Date: 2019-05-22 Impact factor: 1.513
Authors: Winston T Wang; Anika G Patel; Nan Zhang; Scott W Young; J Scott Kriegshauser; Nirvikar Dahiya; Maitray D Patel Journal: Abdom Radiol (NY) Date: 2021-10-04